Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Vaccine
    September 2022
  1. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    >> Share

    July 2022
  2. OSTROPOLETS A, Shoener Dunham L, Johnson KD, Liu J, et al
    Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.
    Vaccine. 2022 Jul 5. pii: S0264-410X(22)00837.
    >> Share

  3. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    >> Share

    June 2022
  4. UFFMAN EA, Li SH, Chen JL, Allen N, et al
    Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00828.
    >> Share

  5. CASAGRANDE TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, et al
    Previous biological therapy and impairment of the IFN-gamma/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00703.
    >> Share

  6. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    >> Share

  7. ARAUJO BC, Simakawa R, Munhoz LG, Carmo FB, et al
    Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00774.
    >> Share

  8. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    >> Share

  9. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    >> Share

  10. WROTNIAK BH, Garrett M, Baron S, Sojar H, et al
    Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00719.
    >> Share

  11. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    >> Share

    May 2022
  12. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    >> Share

  13. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    >> Share

  14. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    >> Share

  15. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.
    >> Share

  16. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    >> Share

  17. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    >> Share

    April 2022
  18. PERCIACCANTE A, Asensi V, Cucu AI, Charlier P, et al
    War, pandemic and vaccination - Upcoming health problems by the refugee wave in Europe?
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00465.
    >> Share

    March 2022
  19. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    >> Share

  20. ISHII H, Nakamura-Hoshi M, Shu T, Matano T, et al
    Sendai virus particles carrying target virus glycoproteins for antibody induction.
    Vaccine. 2022 Mar 16. pii: S0264-410X(22)00273.
    >> Share

    February 2022
  21. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    >> Share

  22. KOCHHAR S, Barreira D, Beattie P, Cavaleri M, et al
    Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case.
    Vaccine. 2022 Feb 11. pii: S0264-410X(21)01395.
    >> Share

    January 2022
  23. PANWAR K, Godi A, Cocuzza CE, Andrews N, et al
    Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix(R) or Gardasil(R) vaccine.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00075.
    >> Share

    December 2021
  24. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    >> Share

  25. FACK C, Wood R, Hatherill M, Cobelens F, et al
    The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01488.
    >> Share

    November 2021
  26. ZOU X, He J, Zheng J, Liang M, et al
    Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01532.
    >> Share

  27. BLAIN AE, Reese HE, Marjuki H, Topaz N, et al
    Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01480.
    >> Share

    October 2021
  28. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    >> Share

    September 2021
  29. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    >> Share

  30. ANGSUWATCHARAKON P, Puthanakit T, Bunjoungmanee P, Anugulruengkitt S, et al
    High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01127.
    >> Share

  31. ABREU E SILVA HB, Correa HP, Ribeiro IA, Nascimento VAM, et al
    Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01009.
    >> Share

    August 2021
  32. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    >> Share

  33. HAGAN LM, Dusseau C, Crockett M, Rodriguez T, et al
    COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01078.
    >> Share

  34. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01035.
    >> Share

  35. D'SOUZA MP, Palin AC, Calder T, Golding H, et al
    Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00964.
    >> Share

    July 2021
  36. HUANG Y, Seaton KE, Casapia M, Polakowski L, et al
    AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00827.
    >> Share

    June 2021
  37. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    >> Share

  38. MESHER D, Thomas SL, Linley E, Edmundson C, et al
    Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00580.
    >> Share

  39. CHUA JV, Davis C, Husson JS, Nelson A, et al
    Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00685.
    >> Share

  40. WOLFE LS, Smedley JG 3rd, Bubna N, Hussain A, et al
    Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00668.
    >> Share

    May 2021
  41. GREWAL R, Deeks SL, Hart TA, Cox J, et al
    Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00603.
    >> Share

  42. BENDER MF, Li Y, Ivleva VB, Gowetski DB, et al
    Protein and glycan molecular weight determination of highly glycosylated HIV-1 envelope trimers by HPSEC-MALS.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00634.
    >> Share

  43. GULLA K, Cibelli N, Cooper JW, Fuller HC, et al
    A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00545.
    >> Share

    April 2021
  44. XIRIDOU M, Visser M, Urbanus A, Matser A, et al
    Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00433.
    >> Share

  45. DANIEL M, Liang B, Luo M
    Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00372.
    >> Share

    March 2021
  46. ROSA SS, Prazeres DMF, Azevedo AM, Marques MPC, et al
    mRNA vaccines manufacturing: Challenges and bottlenecks.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00319.
    >> Share

  47. GOBERT C, Van Hauwermeiren C, Quoidbach C, Reschner A, et al
    Tetanus seroprotection in people living with HIV: Risk factors for seronegativity, evaluation of medical history and a rapid dipstick test.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00242.
    >> Share

    January 2021
  48. SEREMBA E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, et al
    Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.
    Vaccine. 2021 Jan 27. pii: S0264-410X(21)00070.
    >> Share

  49. MUGO N, Eckert LO, Odero L, Gakuo S, et al
    Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31587.
    >> Share

  50. AKMATOV MK, Holstiege J, Steffen A, Batzing J, et al
    Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31693.
    >> Share

  51. CALDERA F, Mercer M, Samson SI, Pitt JM, et al
    Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31490.
    >> Share

    December 2020
  52. KOSKAN A, Klasko-Foster L, Stecher C, Rodriguez S, et al
    Human papillomavirus vaccine guideline adherence among Arizona's Medicaid beneficiaries.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31609.
    >> Share

  53. DOUGLASS N, van Diepen MT, Chapman R, Galant S, et al
    Modifications to the HIV-1 SAAVI MVA-C vaccine improve in vitro expression and in vivo immunogenicity.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31591.
    >> Share

    November 2020
  54. EDOKA I, Kohli-Lynch C, Fraser H, Hofman K, et al
    A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Vaccine. 2020 Nov 30. pii: S0264-410X(20)31468.
    >> Share

  55. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31387.
    >> Share

    October 2020
  56. MANGION M, Gelinas JF, Bakhshi Zadeh Gashti A, Azizi H, et al
    Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31367.
    >> Share

  57. CHESSON HW, Meites E, Ekwueme DU, Saraiya M, et al
    Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
    Vaccine. 2020 Oct 26. pii: S0264-410X(20)31312.
    >> Share

  58. MALTEZOU HC, Theodoridou K, Tseroni M, Raftopoulos V, et al
    Influenza vaccination policies for health workers in low-income and middle-income countries: A cross-sectional survey, January-March 2020.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31276.
    >> Share

  59. MCCLUNG N, Burnett J, Wejnert C, Markowitz LE, et al
    Human papillomavirus vaccination coverage among men who have sex with men-National HIV Behavioral Surveillance, United States, 2017.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31081.
    >> Share

  60. YAO L, Wang JY, Bao LN, Fan MX, et al
    DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31259.
    >> Share

    September 2020
  61. TEMPIA S, Moyes J, Cohen AL, Walaza S, et al
    Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 Sep 23. pii: S0264-410X(20)31193.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016